-11.95 (-0.83%) Cipla has received the Establishment Inspection Report (EIR) for its Indore plant, indicating closure of the inspection. The United States Food and Drug Administration (USFDA) had conducted product-specific pre-approval inspection (PAI) at the Indore plant on June 27 and July 1.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.